Jefferies analysts see Dyne Therapeutics as a key beneficiary of Novartis' acquisition of Avidity Biosciences, validating RNA-based therapies for rare muscle diseases. Dyne's potential first-to-market assets and valuation support a Buy rating with a $50 target.